NKTR vs. LCFY

Last updated Apr 1, 2026

Compare and contrast key facts about Nektar Therapeutics (NKTR) and Locafy Ltd (LCFY).

Performance

NKTR vs. LCFY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nektar Therapeutics (NKTR) and Locafy Ltd (LCFY). The values are adjusted to include any dividend payments, if applicable.

NKTR vs. LCFY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
NKTR Nektar Therapeutics	70.18%	203.08%	64.60%	-75.00%	-59.79%
LCFY Locafy Ltd	55.71%	-59.24%	-24.30%	53.82%	-91.17%

Fundamentals

Market Cap NKTR : $1.46B LCFY : $7.92M
EPS NKTR : -$10.15 LCFY : -$1.44
PS Ratio NKTR : 21.05 LCFY : 2.18
PB Ratio NKTR : 16.26 LCFY : 2.07
Total Revenue (TTM) NKTR : $55.23M LCFY : $3.63M
Gross Profit (TTM) NKTR : $55.04M LCFY : $3.63M
EBITDA (TTM) NKTR : -$122.97M LCFY : -$803.06K

Returns By Period

In the year-to-date period, NKTR achieves a 70.18% return, which is significantly higher than LCFY's 55.71% return.

NKTR

• 1D: 10.27%
• 1M: 4.31%
• YTD: 70.18%
• 6M: 26.45%
• 1Y: 605.39%
• 3Y*: 89.68%
• 5Y*: -25.14%
• 10Y*: -10.44%

LCFY

• 1D: 3.81%
• 1M: -8.02%
• YTD: 55.71%
• 6M: -40.44%
• 1Y: -3.33%
• 3Y*: -12.37%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NKTR vs. LCFY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NKTR

NKTR Risk / Return Rank: 98
NKTR Sharpe Ratio Rank: 97
NKTR Sortino Ratio Rank: 99
NKTR Omega Ratio Rank: 97
NKTR Calmar Ratio Rank: 99
NKTR Martin Ratio Rank: 98

LCFY

LCFY Risk / Return Rank: 55
LCFY Sharpe Ratio Rank: 40
LCFY Sortino Ratio Rank: 83
LCFY Omega Ratio Rank: 79
LCFY Calmar Ratio Rank: 36
LCFY Martin Ratio Rank: 37

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NKTR vs. LCFY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and Locafy Ltd (LCFY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NKTR	LCFY	Difference
Sharpe ratio Return per unit of total volatility	3.23	-0.01	+3.24
Sortino ratio Return per unit of downside risk	5.66	2.28	+3.39
Omega ratio Gain probability vs. loss probability	1.64	1.28	+0.36
Calmar ratio Return relative to maximum drawdown	11.81	-0.18	+11.99
Martin ratio Return relative to average drawdown	28.66	-0.28	+28.94
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NKTR vs. LCFY - Sharpe Ratio Comparison

The current NKTR Sharpe Ratio is 3.23, which is higher than the LCFY Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of NKTR and LCFY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NKTR	LCFY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.23	-0.01	+3.24
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.21	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.11	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.01	-0.28	+0.29

Correlation

The correlation between NKTR and LCFY is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NKTR vs. LCFY - Dividend Comparison

Neither NKTR nor LCFY has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NKTR vs. LCFY - Drawdown Comparison

The maximum NKTR drawdown since its inception was -99.61%, roughly equal to the maximum LCFY drawdown of -96.59%. Use the drawdown chart below to compare losses from any high point for NKTR and LCFY.

Drawdown Indicators

	NKTR	LCFY	Difference
Max Drawdown Largest peak-to-trough decline	-99.61%	-96.59%	-3.02%
Max Drawdown (1Y) Largest decline over 1 year	-46.54%	-68.07%	+21.53%
Max Drawdown (5Y) Largest decline over 5 years	-97.93%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-99.61%	—	—
Current Drawdown Current decline from peak	-95.58%	-93.47%	-2.11%
Average Drawdown Average peak-to-trough decline	-68.16%	-88.61%	+20.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.18%	43.56%	-24.38%

Volatility

NKTR vs. LCFY - Volatility Comparison

The current volatility for Nektar Therapeutics (NKTR) is 16.98%, while Locafy Ltd (LCFY) has a volatility of 22.77%. This indicates that NKTR experiences smaller price fluctuations and is considered to be less risky than LCFY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NKTR	LCFY	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.98%	22.77%	-5.79%
Volatility (6M) Calculated over the trailing 6-month period	65.60%	70.56%	-4.96%
Volatility (1Y) Calculated over the trailing 1-year period	189.57%	253.09%	-63.52%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	121.46%	179.42%	-57.96%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.96%	179.42%	-82.46%

Financials